Online inquiry

IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5534MR)

This product GTTS-WQ5534MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD40LG gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000074.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 959
UniProt ID P29965
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5534MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7933MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ9577MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ5967MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CLLB8
GTTS-WQ6080MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CNTO 888
GTTS-WQ8286MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HM10560A
GTTS-WQ6355MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ4392MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-224818
GTTS-WQ9837MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JTX-2011
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW